UM-UC-3 Orthotopic Mouse Model Service for Bladder Cancer

The UM-UC-3 orthotopic mouse model recapitulates human muscle-invasive bladder cancer within its native urothelial niche, leveraging a p53-null, PTEN-deficient human cell line that exhibits basal-like morphology and robust epithelial-to-mesenchymal transition potential in an immunodeficient host. Alfa Cytology delivers this human xenograft platform with optimized trypsin preconditioning, shallow-catheter surgical technique, and rigorous histopathological staging, ensuring reproducible microlesion-to-invasion progression and quantifiable therapeutic readouts for your discovery program.

Overview of UM-UC-3 Orthotopic Mouse Model for Bladder Cancer

UM-UC-3 is a hypotriploid human urothelial carcinoma cell line originally established from a metastatic lymph node of a male patient with bladder transitional cell carcinoma. The line harbors a homozygous deletion of TP53, loss of RB1, and a partial homozygous deletion of PTEN, resulting in constitutive PI3K/AKT pathway activation and unchecked cell-cycle progression. An activating HRAS mutation together with high TERT promoter activity confers aggressive proliferation and telomerase-driven immortality. Phenotypically, UM-UC-3 displays a basal-like, poorly differentiated state marked by E-cadherin and uroplakin negativity, elevated vimentin and N-cadherin expression, and strong MMP-9 activity—features indicative of epithelial-to-mesenchymal transition and high invasive capacity. When instilled orthotopically into the bladder lumen of athymic nude mice following urothelial preconditioning, UM-UC-3 cells seed discrete microlesions on the lamina propria that progress through superficial carcinoma and carcinoma in situ to full-thickness muscle invasion within approximately three weeks, closely mirroring the pathological trajectory of recurrent human bladder cancer after incomplete resection.

Fig 1. LN stromal HK cells stimulate UCC tumor growth in the IB model. (Gills, Jessie, et al., 2018)

The model offers a 90–100% tumor-seeding efficiency when optimized protocols are applied, including shallow catheter insertion to avoid bladder-wall trauma, prewarmed trypsin or poly-L-lysine pretreatment to remove transitional epithelium, and controlled urethral clamping with body-temperature maintenance during cell dwell. Tumor growth is highly responsive to platinum-based agents such as cisplatin, while showing partial sensitivity to gemcitabine, aligning with clinical chemotherapy profiles. For optical tracking, luciferase-transfected UM-UC-3-luc derivatives enable bioluminescence quantification that correlates linearly with tumor cell number and can be corroborated by small-animal ultrasound, providing a multimodal monitoring framework for longitudinal drug-efficacy assessment in a human-tumor microenvironment.

Cell Line Information: UM-UC-3

UM-UC-3 is a well-characterized human bladder carcinoma line with defined oncogenic driver alterations, basal-like differentiation status, and rapid orthotopic tumorigenicity in immunodeficient mice. The table below summarizes its genetic, phenotypic, and technical parameters for preclinical study design.

Our Services

Alfa Cytology specializes in the construction and analytical support of human orthotopic bladder cancer xenografts, deploying UM-UC-3 cells with authenticated oncogenic profiles, optimized immunodeficient host selection, and standardized intravesical instillation protocols. Our team manages every phase—from cell-line QC and preconditioning optimization through longitudinal tumor monitoring and terminal histopathological staging—ensuring that your preclinical dataset reflects human disease biology with the fidelity required for downstream translational decision-making.

Workflow of UM-UC-3 Orthotopic Mouse Model Construction

Construction of the UM-UC-3 orthotopic xenograft demands precise control of catheter depth, urothelial preconditioning chemistry, and cell-dwell conditions to achieve high engraftment rates while minimizing off-target seeding and procedural morbidity. The workflow below reflects optimized methodologies validated for human bladder cancer preclinical research.

1. Cell Preparation and Quality Control: UM-UC-3 cells are expanded in complete EMEM EBSS medium and harvested during exponential growth phase. Viability is assessed by trypan blue exclusion, with only suspensions exceeding 90% viability accepted for implantation. For standard orthotopic studies, cells are washed twice in PBS to remove residual serum, then resuspended at 1×10⁸ cells/mL in serum-free medium or PBS. For luciferase-tracked studies (UM-UC-3-luc), an in vitro bioluminescence assay is performed to confirm signal linearity and homogeneous reporter expression prior to implantation.
2. Animal Preparation and Anesthesia: Female athymic nude mice (nu/nu), 6–8 weeks old, are acclimatized for a minimum of one week under SPF barrier conditions. On the procedure day, general anesthesia is induced via isoflurane inhalation (3% for induction, 1.8% maintenance at 2 L/min oxygen) or intraperitoneal sodium pentobarbital (60 mg/kg). Depth of anesthesia is confirmed by absence of the toe-pinch reflex. Mice are placed on a heated surgical pad in supine position, and the bladder is manually emptied by gentle suprapubic compression.
3. Urothelial Preconditioning: A sterile 25-gauge catheter is inserted transurethrally to a shallow depth (~1 cm from the urethral meatus) to avoid bladder-wall trauma and hemorrhage. The urothelial barrier is disrupted by instilling either 50 µL of 0.1% poly-L-lysine or 50 µL of 0.2% prewarmed trypsin (37°C) into the bladder lumen. The preconditioning agent is retained for 15 minutes with the mouse maintained on a heated surface to preserve body temperature and enzymatic activity. The solution is then aspirated and the bladder gently emptied.
4. Intravesical Cell Instillation and Retention: The prepared UM-UC-3 cell suspension—typically 3×10⁶ to 1×10⁷ cells in 50–100 µL serum-free medium supplemented with Matrigel for enhanced adhesion—is instilled through the indwelling catheter. A Vascu-Statt plastic clamp (midi, angled) is applied around the urethral meatus to prevent leakage. The inoculum is retained within the bladder for 1.5 hours with the mouse maintained under continuous anesthesia and monitored for respiratory pattern, skin color, and temperature stability.
5. Post-Instillation Recovery and Health Surveillance: After the dwell period, the clamp and catheter are removed and the bladder is allowed to empty spontaneously. Mice are transferred to a warmed recovery chamber and monitored until fully mobile and urinating normally. Body weight, hydration status, hematuria, and general behavior are recorded daily for the first 72 hours. Analgesia is provided according to institutional IACUC guidelines. Mice exhibiting >15% body-weight loss, persistent hematuria, or urinary obstruction are flagged for veterinary assessment.
6. Longitudinal Tumor Monitoring: For UM-UC-3-luc cohorts, tumor establishment and growth are quantified via bioluminescence imaging following intraperitoneal D-luciferin injection (150 µg/g body weight), typically performed twice weekly. Photon flux values are recorded within standardized regions of interest and correlated with small-animal ultrasound for anatomical validation. In standard UM-UC-3 studies, tumor progression is inferred from body-weight trajectories, hematuria scoring, and periodic micro-CT imaging where indicated.
7. Endpoint Necropsy and Histopathological Staging: Mice are euthanized upon reaching humane endpoints (e.g., >20% body-weight loss, severe hydronephrosis, or moribundity) or protocol-defined timepoints. The bladder is excised, weighed, opened longitudinally, and inspected for tumor burden, muscle invasion, and multifocality. Systematic examination of the kidneys, ureters, liver, and lungs is performed to assess off-target seeding. Tissues are processed for hematoxylin and eosin (H&E) staining, immunohistochemistry (E-cadherin, vimentin, Ki-67, CD31), and molecular extraction (RNA/DNA/protein) as dictated by study objectives.

Fig 2. UM-UC-3 Orthotopic Mouse Model construction workflow.

Case Study-UM-UC-3 Orthotopic Mouse Model Development

In a recent preclinical collaboration, Alfa Cytology established a UM-UC-3 orthotopic cohort to evaluate a novel intravesical platinum-prodrug formulation designed to enhance urothelial retention while minimizing systemic toxicity. Following standardized trypsin preconditioning and shallow-catheter instillation, all study animals developed bladder tumors with 90% engraftment efficiency, exhibiting progression from lamina-propria microlesions to muscle-invasive disease within the anticipated three-week window. The experimental design incorporated an intravesical mitomycin C reference arm, a low-dose platinum-prodrug arm, and a combination arm pairing the prodrug with a VEGF-targeting antibody. Terminal histopathology revealed treatment-dependent reductions in muscle-invasion depth and Ki-67 proliferation indices, while immunohistochemical staining showed diminished CD31⁺ microvessel density in the combination-treated group. These preclinical findings provided the sponsor with pharmacodynamic evidence supporting formulation refinement and dose-scheduling optimization for subsequent IND-enabling studies.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your UM-UC-3 orthotopic xenograft study provides access to a human-tumor preclinical platform where molecularly authenticated cell lines, refined surgical technique, and comprehensive endpoint analytics converge to de-risk therapeutic development decisions.

• Molecularly authenticated UM-UC-3 cells with documented TP53, RB1, PTEN, and HRAS status ensure that your preclinical model reflects the oncogenic drivers of aggressive human bladder cancer.
• Optimized shallow-catheter and preconditioning protocols achieve 90–100% orthotopic engraftment while minimizing bladder-wall trauma, hemorrhage, and off-target ureteral seeding.
• The human xenograft format preserves human tumor-cell intrinsic biology and drug-response profiles, offering superior translatability over murine syngeneic lines for certain mechanistic questions.
• Multimodal tumor monitoring—including bioluminescence imaging, small-animal ultrasound, and micro-CT—provides flexible, longitudinal readouts tailored to compound mechanism and study design.
• Comprehensive histopathological staging with muscle-invasion scoring, proliferation indices, and vascular density quantification delivers granular pharmacodynamic data aligned with human pathology standards.
• All studies are conducted within SPF barrier facilities under IACUC-approved protocols, with full chain-of-custody documentation and GLP-compatible data packages available upon request.

Contact Us

If your bladder cancer research program requires a human-derived, molecularly defined orthotopic model with proven engraftment efficiency and clinically relevant pathological progression, reach out to Alfa Cytology to discuss how our UM-UC-3 platform can accelerate your preclinical development. Our scientific team will design a customized study architecture, select optimal monitoring modalities for your therapeutic candidate, and provide a comprehensive project proposal. Contact us today to bridge human tumor biology with actionable translational data.

For research use only. Not intended for any clinical use.